1. Novel and Emerging Approaches to Treating CLL

3. Treatment Strategies for Patients With CLL

4. Response to FCR

5. CLL10 Study: FCR vs BR in Front Line

6. CLL10 Study: Progression-Free Survival

7. CLL11 Study: Design

8. Head-to-Head PFS

9. Targeting of BCR Signaling in CLL

10. Ibrutinib in Refractory CLL With del(11q)

11. Best Response With Ibrutinib

12. Platelet Counts and Hemoglobin Levels

13. Updated PFS With Ibrutinib

14. Common AEs With Ibrutinib

15. RESONATE Phase 3

16. Atrial Fibrillation and Bleeding-Related AEs With Ibrutinib

17. Improvement of Baseline Cytopenias With Idelalisib

18. Nodal and ORR With Idelalisib

19. Study 116: A Randomized, Double-Blind, Placebo-Controlled Study

20. Study 116: Key Eligibility

23. Venetoclax: Dose Escalation Schematic

24. Venetoclax: CRR and ORR by Subgroups

25. Additional Outcomes With Venetoclax

26. Venetoclax Safety Results

27. RESONATE-2: Study Design

28. RESONATE-2: Patient Characteristics

29. RESONATE-2: ORR in the Ibrutinib Arm

30. RESONATE-2: 24-Mo PFS

31. Most Patients Remain on Ibrutinib Treatment

32. Response to FCR

33. Effect of IGHV Mutational Status on PFS

34. Treatment Strategies for Patients With CLL

35. Obinutuzumab Combined With Venetoclax

36. Venetoclax, Ibrutinib, and Obinutuzumab Combination Therapy

37. Concluding Remarks

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)